Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (July 2021)
34 slides from Cocrystal Pharma's investor presentation, Jul 12, 2021
Slide 1: Investor Presentation July 2021
NASDAQ: COCP. cocrystalpharma.com CCRYSTAL | Investor Presentation PHARMA,INC. July 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our progra
Slide 3: About Cocrystal Pharma
IOI About Cocrystal Pharma Clinical-Stage Antiviral Company Influenza Proprietary Drug Discovery Platform eae Merck Collaboration Hepatitis C Potential For Prophylactic and Therapeutic Drugs Norovirus Gastroenteritis
Slide 4: Investment Highlights
N ¢ Investment Highlights Applying proprietary structure-based drug design technology to develop first- and best- in-class broad-spectrum antiviral drugs Large market opportunities for the treatment of acute and chronic viral diseases including seasonal and pandemic influenza, COVID-19, hepatitis C,
Slide 5: Seasoned Leadership
Sam Lee, Ph.D. Interim Co-Chief Executive Officer & President + 25+ years of anti-infective drug discovery research experience; played key role in early development of phosphoinositide 3-kinase (PI3K) delta inhibitors James J. Martin, MBA, CPA Interim Co-Chief Executive Officer & Chief Financial Off
Slide 6: Technology Platform
Technology Platform Based on Nobel Prize-winning technology * Near-atomic resolution + X-ray quality crystal production + Drug pocket selection * Hit-to-lead process + Lead optimization EEEEE - Drug candidates Proprietary Technology and Drug Discovery Platform Dru: covery Platform Crystal Production
Slide 7: Robust Development Pipeline in High-Value Indications
Robust Development Pipeline in High-Value Indications Program Discovery | Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Influenza A/B | Influenza AJB inhibitor i> In collaboration with C=) MERCK nfluenza amino > Influenza A PB2 Inhibitor eae CDI-45205 (censesrom Protease Inhibitor KSURF) covip-19 Re
Slide 8: Overview | Antiviral Program: Influenza A/B Merck Collaboration
Overview | Antiviral Program: Influenza A/B Merck Collaboration
Slide 9: Influenza A/B Merck Collaboration
PS Lol Influenza A/B Merck Collaboration © MERCK Influenza A/B Crystals ¢ Broad-spectrum, potent dual influenza A/B drug candidates ¢ Binds to highly conserved site of influenza A and B replication complex ¢ Expected to be active against seasonal, pandemic and existing drug- resistant influenza A an
Slide 10: Collaboration Terms Overview
at&t ; : Lol Collaboration Terms Overview Eligible to receive up to $156 million in milestone payments + royalties on product sales « Exclusive worldwide license and collaboration agreement to discover and develop proprietary influenza A/B antiviral agents signed in January 2019 e Agreement structur
Slide 11: Overview | Antiviral Program: COVID-19
1 Overview | Antiviral Program: COVID-19
Slide 12: Kansas State University Research Foundation Agreements
mS @1 Kansas State University Research Foundation Agreements xT Cocrystal acquired exclusive patent rights and know-how for coronavirus and norovirus therapeutics for human use * License agreements with KSURF in 2020 to further develop proprietary broad-spectrum compounds for coronavirus and norovir
Slide 13: Status of COVID-19 Treatment
N N Status of COVID-19 Treatment Cocrystal is researching and developing multiple options needed to prevent or treat COVID-19 There is no approved COVID-19 antiviral prophylactic treatment There is no currently approved or authorized oral COVID-19 antiviral treatment of mild-to-moderate COVID-19 in
Slide 14: Stages of COVID-19
\N Cl 2 Stages of COVID-19 Stage | Stage Il Stage Ill (Early Infection) (Pulmonary Phase) (Hyperinflammation Phase) 4 N Severity of Illness Host inflammatory response phase Fas Time course Mild constitutional symptoms Shortness of breath without ARDS Clinical Symptoms Fever >99.6°F (IIA) and hypoxia
Slide 15: Need for Therapies Targeting SARS-CoV-2 Replication
ONS Lol Need for Therapies Targeting SARS-CoV-2 Replication “The bottom line of what we need to do looking forward, and the clear need in this, is the development of potent antivirals directly acting on SARS-CoV-2. “Very similar to what was done with the highly successful drug development program fo
Slide 16: COVID-19 Program Status
mS Lol COVID-19 Program Status ¢ Potential first-in-class therapeutic and prophylactic treatment ° Develop SARS-CoV-2 inhibitors using proprietary platform technology * Targeting viral replication complex and protease Achieved Milestones and Next Steps: v Q4 2020 CDI-45205 Selected as Preclinical Le
Slide 17: Overview | Antiviral Program: Pandemic Influenza A
17 Overview | Antiviral Program: Pandemic Influenza A
Slide 18: Significant Need for Pandemic Influenza Therapies
PS Lol Significant Need for Pandemic Influenza Therapies Seasonal and pandemic infections 4 Billion 3-5 Million Up to 650,000 cases of severe deaths worldwide cases annually? : y illness annually’ annually’ Current antiviral treatments are burdened by significant viral resistance Approved influenza
Slide 19: Influenza Remains a Major U.S. and Global Concern
“ oe Fitness | V\ Flu season deaths top 80,000 last year, CDC says Influenza Remains a Major U.S. and Global Concern September 27, 2018 US on track for one of TV. the worst flu seasons in decades Jan, 6, 2020 Science Swine flu strain with human pandemic potential increasingly found in pigs in China
Slide 20: CC-42344 Shows Strong Synergistic Effects with Approved Influenza Antivirals
ror CC-42344 Shows Strong Synergistic Effects with ad Approved Influenza Antivirals Polymerase Inhibitor Favipiravir = /n vitro combination studies with Xofluza, Tamiflu, and Favipiravir demonstrated strong synergistic NY effects - =" CC-42344 shows high barrier to drug resistance and active against
Slide 21: CC-42344: Pharmacological, Safety, Toxicity and PK Evaluations Successfully Completed
ror CC-42344: Pharmacological, Safety, Toxicity and lana PK Evaluations Successfully Completed In vitro antiviral profiling against seasonal and pandemic influenza A strains Cytotoxicity including larger screen: HepG2/high content analysis and 13 cell lines Caco-2 bidirectional permeability CYP inhi
Slide 22: CC-42344: Influenza A Pandemic Antiviral Drug
PS LI CC-42344: Influenza A Pandemic Antiviral Drug ~TF Binds to the highly conserved pocket on replication enzyme Exhibits broad spectrum activity against seasonal and pandemic influenza strains Favorable preclinical safety profile and pharmacokinetic properties Multiple routes of administration to
Slide 23: Overview | Antiviral Program: Hepatitis C
23 Overview | Antiviral Program: Hepatitis C
Slide 24: Hepatitis C Strategy
Ake sae Lol Hepatitis C Strategy Lead program CC-31244, Phase 2a study completed for the treatment of HCV Current HCV Market Overview Evolution of Shorter Therapy ° Ultrashort treatment siraleay Nucleoside/NSSA Inhibitors Protease/NSSA Inhibitors * Limitations of existing long-term HCV therapies: ¢
Slide 25: CC-31244: HCV Non-Nucleoside Inhibitor (NNI)
N te Lol CC-31244: HCV Non-Nucleoside Inhibitor (NNI) A HCV GT1 — GT6 NS5B Polymerase Crystals Pa Next Generation Combination (Cocktail) Therapy Potential Best-in-Class NNI ¢ Potential best-in-class HCV NNI with a - Treatment strong profile dis Frequency ¢ Broad-spectrum, potent NS5B polymerase cc-3
Slide 26: Favorable HCV Phase 2a Trial Results with CC-31244
mS Lol Favorable HCV Phase 2a Trial Results with CC-31244 6 weeks of Epclusa® therapy including 2 weeks of CC-31244 Treatment was well tolerated with no study discontinuations due to adverse events 8 of 12 subjects (67%) achieved both SVR12 and SVR24, considered virologic cure 4 patients had virolog
Slide 27: Overview | Antiviral Program: Norovirus Gastroenteritis
27 Overview | Antiviral Program: Norovirus Gastroenteritis
Slide 28: Norovirus: No Approved Treatment
\N Cl Norovirus: No Approved Treatment 4 N Norovirus Polymerase and Protease Crystals ee Estimated annual cost of $60 billion worldwide due to healthcare costs and lost productivity’ ~685 Million infections worldwide annually’ 19-21 Million cases in the U.S.1 465,000 emergency department visits in t
Slide 29: Potential for Developing First Norovirus Therapy
PS Lol Potential for Developing First Norovirus Therapy ¢ Potent, broad-spectrum polymerase and protease inhibitors licensed from KSURF ¢ Structure-based lead molecule discovery ongoing Achieved Milestones and Next Steps: ¥ Q2 2020 Filed Additional Patent Application ¢ H22021 Complete Proof-of-Conce
Slide 30: Positioned for Growth
30 Positioned for Growth
Slide 31: Expanding Intellectual Property Portfolio
ONS Ly Expanding Intellectual Property Portfolio _TF * Influenza A/B HCV * Influenza A/B inhibitor NS5B (NNI) * Pending applications in U.S. and Issued patents in U.S. worldwide ; ail : Pending applications in U.S. and F worldwide * Coronavirus . a * Issued patents in U.S. and major countries Pendin
Slide 32: Financial Snapshot
Financial Snapshot A N 16.3 Million Average 3 month daily share volume’ ~$121 Million Market cap 97.5 Million 99.5Million Caniinon Sreves Fully diluted shares outstanding ' ~ * Clean balance sheet ¢ No preferred shares « No debt * Only 243,000 warrants ¢ Cash runway beyond 2024 1 Yahoo Finance 2 Com
Slide 33: Investment Highlights
N ¢ Investment Highlights Applying proprietary structure-based drug design technology to develop first- and best- in-class broad-spectrum antiviral drugs Large market opportunities for the treatment of acute and chronic viral diseases including seasonal and pandemic influenza, COVID-19, hepatitis C,
Slide 34: Thank you!
NASDAQ: COCP. cocrystalpharma.com C@CRYSTAL Thank you! PeteA ReM AG, I NC.